一名接受PI3K抑制剂治疗慢性淋巴细胞白血病的患者发生了风湿性多肌痛。
Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.
作者信息
Sajawal Sanah, Mackie Sarah L, Hillmen Peter, McGonagle Dennis
机构信息
Chapel Allerton Hospital, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
出版信息
BMJ Case Rep. 2017 Nov 8;2017:bcr-2017-221065. doi: 10.1136/bcr-2017-221065.
Abstract
We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3Kδ inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74 mg/L. After 2 weeks of prednisolone 15 mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3Kδ inhibitor treatment of CLL.
摘要
我们报告了一名慢性淋巴细胞白血病（CLL）患者，该患者接受了idelalisib（一种PI3Kδ抑制剂）联合利妥昔单抗治疗。治疗20周后，患者出现了风湿性多肌痛（PMR）的典型体征和症状，同时C反应蛋白升高至74mg/L。在每日服用15mg泼尼松龙2周后，症状缓解，急性期指标恢复正常。据我们所知，这是首例PMR作为CLL患者PI3Kδ抑制剂治疗并发症出现的报告。
相似文献
1
Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.一名接受PI3K抑制剂治疗慢性淋巴细胞白血病的患者发生了风湿性多肌痛。
BMJ Case Rep. 2017 Nov 8;2017:bcr-2017-221065. doi: 10.1136/bcr-2017-221065.
2
Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.idelalisib：一种用于慢性淋巴细胞白血病的新型PI3Kδ抑制剂。
Ann Pharmacother. 2015 Oct;49(10):1162-70. doi: 10.1177/1060028015594813. Epub 2015 Jul 16.
3
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.依鲁替尼治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。
Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.
4
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.idelalisib：用于治疗慢性淋巴细胞白血病、小淋巴细胞白血病和滤泡性淋巴瘤的首款PI3Kδ抑制剂。
Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10.
5
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.idelalisib联合利妥昔单抗对慢性淋巴细胞白血病继发的系统性AL淀粉样变性有效。
Hematol Oncol. 2018 Feb;36(1):366-369. doi: 10.1002/hon.2480. Epub 2017 Oct 3.
6
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.一项关于idelalisib联合利妥昔单抗用于初治老年慢性淋巴细胞白血病患者的2期研究。
Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15.
7
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.idelalisib联合奥法木单抗治疗既往治疗过的慢性淋巴细胞白血病的疗效和安全性：一项开放标签、随机3期试验。
Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4.
8
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).一项回顾性观察研究，评估英国和爱尔兰使用idelalisib 和利妥昔单抗治疗慢性淋巴细胞白血病患者的临床结局和常规管理（RETRO-idel）。
Br J Haematol. 2021 Jul;194(1):69-77. doi: 10.1111/bjh.17475. Epub 2021 Jun 14.
9
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.因毒性而停止治疗后接受一线idelalisib联合利妥昔单抗治疗的慢性淋巴细胞白血病患者的结局
Cancer. 2016 Aug 15;122(16):2505-11. doi: 10.1002/cncr.30069. Epub 2016 May 16.
10
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.依鲁替尼，一种磷酸肌醇 3-激酶 p110δ 的抑制剂，用于治疗复发/难治性慢性淋巴细胞白血病。
Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.
本文引用的文献
1
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.免疫检查点抑制剂治疗后出现的类风湿关节炎和巨细胞动脉炎。
Ann Rheum Dis. 2017 Oct;76(10):1747-1750. doi: 10.1136/annrheumdis-2017-211216. Epub 2017 Jun 9.
2
A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.阿巴西普（CTLA-4Ig）治疗巨细胞动脉炎的随机、双盲试验。
Arthritis Rheumatol. 2017 Apr;69(4):837-845. doi: 10.1002/art.40044. Epub 2017 Mar 3.
3
An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.巨细胞动脉炎中致病性调节性T细胞的扩增群体可通过白细胞介素-6阻断疗法消除。
Ann Rheum Dis. 2017 May;76(5):898-905. doi: 10.1136/annrheumdis-2016-210070. Epub 2016 Dec 7.
4
Comment on: Musculoskeletal complication of haematological disease.
Rheumatology (Oxford). 2017 Feb;56(2):320-321. doi: 10.1093/rheumatology/kew372. Epub 2016 Nov 11.
5
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.一线使用idelalisib治疗慢性淋巴细胞白血病会频繁引发免疫介导的肝毒性。
Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.
6
Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.简要报告：托珠单抗治疗巨细胞动脉炎的前瞻性开放标签 2a 期试验。
Arthritis Rheumatol. 2016 Oct;68(10):2550-4. doi: 10.1002/art.39740.
7
Idelalisib: a rare cause of enterocolitis.idelalisib：小肠结肠炎的罕见病因。
Ann Gastroenterol. 2016 Apr-Jun;29(2):233-5. doi: 10.20524/aog.2016.0022.
8
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.免疫检查点阻断相关的免疫相关不良事件：一项全面综述。
Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5.
9
Idelalisib-associated Colitis: Histologic Findings in 14 Patients.依地那利昔布相关结肠炎：14例患者的组织学表现
Am J Surg Pathol. 2015 Dec;39(12):1661-7. doi: 10.1097/PAS.0000000000000522.
10
2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.2015 年多发性肌痛治疗建议：欧洲抗风湿病联盟/美国风湿病学会合作倡议。
Ann Rheum Dis. 2015 Oct;74(10):1799-807. doi: 10.1136/annrheumdis-2015-207492.
Zotero 插件